22 results on '"Mariani, Marco Valerio"'
Search Results
2. The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum.
- Author
-
D'Amato, Andrea, Severino, Paolo, Prosperi, Silvia, Mariani, Marco Valerio, Germanò, Rosanna, De Prisco, Andrea, Myftari, Vincenzo, Cestiè, Claudia, Labbro Francia, Aurora, Marek-Iannucci, Stefanie, Tabacco, Leonardo, Vari, Leonardo, Marano, Silvia Luisa, Di Pietro, Gianluca, Lavalle, Carlo, Sardella, Gennaro, Mancone, Massimo, Badagliacca, Roberto, Fedele, Francesco, and Vizza, Carmine Dario
- Subjects
HEART failure ,TROPONIN ,MEDIAN (Mathematics) ,PROGNOSIS ,HOSPITAL admission & discharge ,REGRESSION analysis - Abstract
Background: Cardiac troponin release is related to the cardiomyocyte loss occurring in heart failure (HF). The prognostic role of high-sensitivity cardiac troponin T (hs-cTnT) in several settings of HF is under investigation. The aim of the study is to assess the prognostic role of intrahospital hs-cTnT in patients admitted due to HF. Methods: In this observational, single center, prospective study, patients hospitalized due to HF have been enrolled. Admission, in-hospital peak, and discharge hs-cTnT have been assessed. Patients were followed up for 6 months. Cardiovascular (CV) death, HF hospitalization (HFH), and worsening HF (WHF) (i.e., urgent ambulatory visit/loop diuretics escalation) events have been assessed at 6-month follow up. Results: 253 consecutive patients have been enrolled in the study. The hs-cTnT median values at admission and discharge were 0.031 ng/mL (IQR 0.02–0.078) and 0.031 ng/mL (IQR 0.02–0.077), respectively. The risk of CV death/HFH was higher in patients with admission hs-cTnT values above the median (p = 0.02) and in patients who had an increase in hs-cTnT during hospitalization (p = 0.03). Multivariate Cox regression analysis confirmed that hs-cTnT above the median (OR: 2.06; 95% CI: 1.02–4.1; p = 0.04) and increase in hs-cTnT during hospitalization (OR:1.95; 95%CI: 1.006–3.769; p = 0.04) were predictors of CV death/HFH. In a subgroup analysis of patients with chronic HF, hs-cTnT above the median was associated with increased risk of CV death/HFH (p = 0.03), while in the subgroup of patients with HFmrEF/HFpEF, hs-cTnT above the median was associated with outpatient WHF events (p = 0.03). Conclusions: Inpatient hs-cTnT levels predict CV death/HFH in patients with HF. In particular, in the subgroup of chronic HF patients, hs-cTnT is predictive of CV death/HFH; while in patients with HFmrEF/HFpEF, hs-cTnT predicts WHF events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic Assessment of HLM Score in Heart Failure Due to Ischemic Heart Disease: A Pilot Study.
- Author
-
D'Amato, Andrea, Severino, Paolo, Mancone, Massimo, Mariani, Marco Valerio, Prosperi, Silvia, Colombo, Lorenzo, Myftari, Vincenzo, Cestiè, Claudia, Labbro Francia, Aurora, Germanò, Rosanna, Pierucci, Nicola, Fanisio, Francesca, Marek-Iannucci, Stefanie, De Prisco, Andrea, Scoccia, Gianmarco, Birtolo, Lucia Ilaria, Manzi, Giovanna, Lavalle, Carlo, Sardella, Gennaro, and Badagliacca, Roberto
- Subjects
CORONARY disease ,MYOCARDIAL ischemia ,HEART failure ,ACUTE coronary syndrome ,PILOT projects - Abstract
Background: Ischemic heart disease (IHD) represents the main cause of heart failure (HF). A prognostic stratification of HF patients with ischemic etiology, particularly those with acute coronary syndrome (ACS), may be challenging due the variability in clinical and hemodynamic status. The aim of this study is to assess the prognostic power of the HLM score in a population of patients with ischemic HF and in a subgroup who developed HF following ACS. Methods: This is an observational, prospective, single-center study, enrolling consecutive patients with a diagnosis of ischemic HF. Patients were stratified according to the four different HLM stages of severity, and the occurrence of CV death, HFH, and worsening HF events were evaluated at 6-month follow-up. A sub-analysis was performed on patients who developed HF following ACS at admission. Results: The study included 146 patients. HLM stage predicts the occurrence of CV death (p = 0.01) and CV death/HFH (p = 0.003). Cox regression analysis confirmed HLM stage as an independent predictor of CV death (OR: 3.07; 95% IC: 1.54–6.12; p = 0.001) and CV death/HFH (OR: 2.45; 95% IC: 1.43–4.21; p = 0.001) in the total population of patients with HF due to IHD. HLM stage potentially predicts the occurrence of CV death (p < 0.001) and CV death/HFH (p < 0.001) in patients with HF following ACS at admission. Conclusions: Pathophysiological-based prognostic assessment through HLM score is a potentially promising tool for the prediction of the occurrence of CV death and CV death/HFH in ischemic HF patients and in subgroups of patients with HF following ACS at admission. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Pulsed Field Energy in Atrial Fibrillation Ablation: From Physical Principles to Clinical Applications.
- Author
-
Pierucci, Nicola, Mariani, Marco Valerio, Laviola, Domenico, Silvetti, Giacomo, Cipollone, Pietro, Vernile, Antonio, Trivigno, Sara, La Fazia, Vincenzo Mirco, Piro, Agostino, Miraldi, Fabio, Vizza, Carmine Dario, and Lavalle, Carlo
- Subjects
- *
ATRIAL fibrillation , *MYOCARDIAL depressants , *CLINICAL medicine , *PHRENIC nerve , *CATHETER ablation , *DRUG efficacy , *ARRHYTHMIA , *ATRIAL flutter - Abstract
Atrial fibrillation, representing the most prevalent sustained cardiac arrhythmia, significantly impacts stroke risk and cardiovascular mortality. Historically managed with antiarrhythmic drugs with limited efficacy, and more recently, catheter ablation, the interventional approach field is still evolving with technological advances. This review highlights pulsed field ablation (PFA), a revolutionary technique gaining prominence in interventional electrophysiology because of its efficacy and safety. PFA employs non-thermal electric fields to create irreversible electroporation, disrupting cell membranes selectively within myocardial tissue, thus preventing the non-selective damage associated with traditional thermal ablation methods like radiofrequency or cryoablation. Clinical studies have consistently shown PFA's ability to achieve pulmonary vein isolation—a cornerstone of AF treatment—rapidly and with minimal complications. Notably, PFA reduces procedure times and has shown a lower incidence of esophageal and phrenic nerve damage, two common concerns with thermal techniques. Emerging from oncological applications, the principles of electroporation provide a unique tissue-selective ablation method that minimizes collateral damage. This review synthesizes findings from foundational animal studies through to recent clinical trials, such as the MANIFEST-PF and ADVENT trials, demonstrating PFA's effectiveness and safety. Future perspectives point towards expanding indications and refinement of techniques that promise to improve AF management outcomes further. PFA represents a paradigm shift in AF ablation, offering a safer, faster, and equally effective alternative to conventional methods. This synthesis of its development and clinical application outlines its potential to become the new standard in AF treatment protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Mechanical Circulatory Support Systems in the Management of Ventricular Arrhythmias: A Contemporary Overview.
- Author
-
Mariani, Marco Valerio, Pierucci, Nicola, Cipollone, Pietro, Vignaroli, Walter, Piro, Agostino, Compagnucci, Paolo, Matteucci, Andrea, Chimenti, Cristina, Pandozi, Claudio, Dello Russo, Antonio, Miraldi, Fabio, Vizza, Carmine Dario, and Lavalle, Carlo
- Subjects
- *
VENTRICULAR arrhythmia , *ARTIFICIAL blood circulation , *THUNDERSTORMS , *CATHETER ablation , *CARDIAC output , *MYOCARDIAL perfusion imaging , *HEART assist devices - Abstract
Ventricular tachycardias (VTs) and electrical storms (ES) are life-threatening conditions mostly seen in the setting of structural heart disease (SHD). Traditional management strategies, predominantly centered around pharmacological interventions with antiarrhythmic drugs, have demonstrated limited efficacy in these cases, whereas catheter ablation is related with more favorable outcomes. However, patients with hemodynamically unstable, recurrent VT or ES may present cardiogenic shock (CS) that precludes the procedure, and catheter ablation in patients with SHD portends a multifactorial intrinsic risk of acute hemodynamic decompensation (AHD), that is associated with increased mortality. In this setting, the use of mechanical circulatory support (MCS) systems allow the maintenance of end-organ perfusion and cardiac output, improving coronary flow and myocardial mechanics, and minimizing the effect of cardiac stunning after multiple VT inductions or cardioversion. Although ablation success and VT recurrence are not influenced by hemodynamic support devices, MCS promotes diuresis and reduces the incidence of post-procedural kidney injury. In addition, MCS has a role in post-procedural mortality reduction at long-term follow-up. The current review aims to provide a deep overview of the rationale and modality of MCS in patients with refractory arrhythmias and/or undergoing VT catheter ablation, underlining the importance of patient selection and timing for MCS and summarizing reported clinical experiences in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Probability Score to Predict Spontaneous Conversion to Sinus Rhythm in Patients with Symptomatic Atrial Fibrillation When Less Could Be More?
- Author
-
Mariani, Marco Valerio, Pierucci, Nicola, Trivigno, Sara, Cipollone, Pietro, Piro, Agostino, Chimenti, Cristina, Della Rocca, Domenico Giovanni, Miraldi, Fabio, Vizza, Carmine Dario, and Lavalle, Carlo
- Subjects
- *
ATRIAL fibrillation , *PROBABILITY theory , *RHYTHM , *HOSPITAL emergency services - Abstract
Background: The probability of spontaneous conversion (SCV) to sinus rhythm (SR) in patients presenting to the emergency department (ED) with hemodynamically stable, symptomatic atrial fibrillation (AF) is not well known. Objective: To develop and validate a score to determine the probability of SCV to SR in patients presenting to the ED with hemodynamically stable, symptomatic AF. Methods: This retrospective, observational study enrolled consecutive patients admitted with AF to the ED. Variables associated to SCV during a 6 h "wait-and-see" approach were used to develop and validate a score to determine the probability of SCV to SR in AF patients. The study was divided in two phases: (1) score development and (2) validation of the predictive score. Results: Out of 748 eligible patients, 446 patients were included in the derivation cohort, whereas 302 patients were included in the validation cohort. In the derivation cohort, based on multivariable logistic analysis, a probability score weight was developed including: previous SCV (3 points), AF-related symptom duration < 24 h (5 points), age ≥ 65 years (3 points) and female sex (2 points). The score allowed us to divide patients in three groups based on the probability of SCV to SR during the 6 h observation period. The probability prediction model showed an area under the curve (AUC) of 0.707 and 0.701 in the derivation and validation cohorts, respectively. Conclusions: The proposed score allowed us to predict SCV probability with good accuracy and may help physicians in tailoring AF management in an effective and timely manner. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights.
- Author
-
D'Amato, Andrea, Prosperi, Silvia, Severino, Paolo, Myftari, Vincenzo, Labbro Francia, Aurora, Cestiè, Claudia, Pierucci, Nicola, Marek-Iannucci, Stefanie, Mariani, Marco Valerio, Germanò, Rosanna, Fanisio, Francesca, Lavalle, Carlo, Maestrini, Viviana, Badagliacca, Roberto, Mancone, Massimo, Fedele, Francesco, and Vizza, Carmine Dario
- Subjects
HEART failure ,GUANYLATE cyclase ,RENIN-angiotensin system ,LIFE expectancy ,CLINICAL deterioration ,BETA adrenoceptors - Abstract
Worsening heart failure (WHF) is a severe and dynamic condition characterized by significant clinical and hemodynamic deterioration. It is characterized by worsening HF signs, symptoms and biomarkers, despite the achievement of an optimized medical therapy. It remains a significant challenge in cardiology, as it evolves into advanced and end-stage HF. The hyperactivation of the neurohormonal, adrenergic and renin-angiotensin-aldosterone system are well known pathophysiological pathways involved in HF. Several drugs have been developed to inhibit the latter, resulting in an improvement in life expectancy. Nevertheless, patients are exposed to a residual risk of adverse events, and the exploration of new molecular pathways and therapeutic targets is required. This review explores the current landscape of WHF, highlighting the complexities and factors contributing to this critical condition. Most recent medical advances have introduced cutting-edge pharmacological agents, such as guanylate cyclase stimulators and myosin activators. Regarding device-based therapies, invasive pulmonary pressure measurement and cardiac contractility modulation have emerged as promising tools to increase the quality of life and reduce hospitalizations due to HF exacerbations. Recent innovations in terms of WHF management emphasize the need for a multifaceted and patient-centric approach to address the complex HF syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Spontaneous Coronary Artery Dissection in Clinical Practice: Pathophysiology and Therapeutic Approaches.
- Author
-
D'Amato, Andrea, Mariani, Marco Valerio, Prosperi, Silvia, Colombo, Lorenzo, De Prisco, Andrea, Lavalle, Carlo, Mancone, Massimo, Vizza, Carmine Dario, and Severino, Paolo
- Subjects
SPONTANEOUS coronary artery dissection ,CORONARY artery bypass ,PERCUTANEOUS coronary intervention ,PATHOLOGICAL physiology ,MYOCARDIAL infarction ,CORONARY artery disease ,MUCOCUTANEOUS lymph node syndrome - Abstract
Spontaneous coronary artery dissection (SCAD) is a cause of myocardial infarction without obstructive coronary artery disease (MINOCA). It is determined by a coronary artery wall layers separation, which occurs regardless of traumatic or iatrogenic injuries. Even if it is often a missed diagnosis, its incidence is growing along with the improvement of intracoronary imaging techniques that allow for better detection. The main angiographical classification distinguishes three different forms, with slightly different prognoses at long-term follow up. SCAD is a recurrent condition, severely hampering the life quality of affected patients. The predominantly young age of patients with SCAD and the high prevalence of females among them have made the topic increasingly important, especially regarding therapeutic strategies. According to the data, the most recommended treatment is conservative, based on the use of antiplatelet agents and supportive anti-ischemic therapy. However, there are conflicting opinions concerning the need for dual antiplatelet therapy and its duration. In the case of invasive treatment, the choice between percutaneous coronary intervention and coronary artery bypass graft depends on the patient's clinical stability and the interested vessel. The purpose of the current review is to revise the pathophysiological mechanisms underlying SCAD and the current knowledge of its treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Inherited Arrhythmias in the Pediatric Population: An Updated Overview.
- Author
-
Mariani, Marco Valerio, Pierucci, Nicola, Fanisio, Francesca, Laviola, Domenico, Silvetti, Giacomo, Piro, Agostino, La Fazia, Vincenzo Mirco, Chimenti, Cristina, Rebecchi, Marco, Drago, Fabrizio, Miraldi, Fabio, Natale, Andrea, Vizza, Carmine Dario, and Lavalle, Carlo
- Subjects
ARRHYTHMOGENIC right ventricular dysplasia ,CHILD patients ,HEART abnormalities ,BRUGADA syndrome ,HEART diseases ,ARRHYTHMIA - Abstract
Pediatric cardiomyopathies (CMs) and electrical diseases constitute a heterogeneous spectrum of disorders distinguished by structural and electrical abnormalities in the heart muscle, attributed to a genetic variant. They rank among the main causes of morbidity and mortality in the pediatric population, with an annual incidence of 1.1–1.5 per 100,000 in children under the age of 18. The most common conditions are dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Despite great enthusiasm for research in this field, studies in this population are still limited, and the management and treatment often follow adult recommendations, which have significantly more data on treatment benefits. Although adult and pediatric cardiac diseases share similar morphological and clinical manifestations, their outcomes significantly differ. This review summarizes the latest evidence on genetics, clinical characteristics, management, and updated outcomes of primary pediatric CMs and electrical diseases, including DCM, HCM, arrhythmogenic right ventricular cardiomyopathy (ARVC), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome (LQTS), and short QT syndrome (SQTS). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events.
- Author
-
Lavalle, Carlo, Di Lullo, Luca, Jabbour, Jean Pierre, Palombi, Marta, Trivigno, Sara, Mariani, Marco Valerio, Summaria, Francesco, Severino, Paolo, Badagliacca, Roberto, Miraldi, Fabio, Bellasi, Antonio, and Vizza, Carmine Dario
- Subjects
HEART failure ,VENTRICULAR ejection fraction ,PATIENT experience ,SYMPTOMS ,CARDIOVASCULAR disease related mortality ,PATIENTS' attitudes - Abstract
Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed "worsening heart failure" (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with "stable" HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist.
- Author
-
Di Lullo, Luca, Lavalle, Carlo, Scatena, Alessia, Mariani, Marco Valerio, Ronco, Claudio, and Bellasi, Antonio
- Subjects
DIABETIC nephropathies ,MINERALOCORTICOID receptors ,TYPE 2 diabetes ,SODIUM-glucose cotransporter 2 inhibitors ,CHRONIC kidney failure ,DIABETES complications - Abstract
Chronic kidney disease (CKD) is one of the most common complications of diabetes mellitus and an independent risk factor for cardiovascular disease. Despite guideline-directed therapy of CKD in patients with type 2 diabetes, the risk of renal failure and cardiovascular events still remains high, and diabetes remains the leading cause of end-stage kidney disease in affected patients. To date, current medications for CKD and type 2 diabetes mellitus have not reset residual risk in patients due to a high grade of inflammation and fibrosis contributing to kidney and heart disease. This question-and-answer-based review will discuss the pharmacological and clinical differences between finerenone and other mineralocorticoid receptor antagonists and then move on to the main evidence in the cardiovascular and renal fields, closing, finally, on the potential role of therapeutic combination with sodium-glucose cotransporter 2 inhibitors (SGLT2is). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Protection against Ischemic Heart Disease: A Joint Role for eNOS and the K ATP Channel.
- Author
-
Severino, Paolo, D'Amato, Andrea, Mancone, Massimo, Palazzuoli, Alberto, Mariani, Marco Valerio, Prosperi, Silvia, Myftari, Vincenzo, Lavalle, Carlo, Forleo, Giovanni Battista, Birtolo, Lucia Ilaria, Caputo, Viviana, Miraldi, Fabio, Chimenti, Cristina, Badagliacca, Roberto, Maestrini, Viviana, Palmirotta, Raffaele, Vizza, Carmine Dario, and Fedele, Francesco
- Subjects
MYOCARDIAL ischemia ,CORONARY disease ,POTASSIUM channels ,CORONARY circulation ,NITRIC-oxide synthases ,JOINT diseases - Abstract
Genetic susceptibility may influence ischemic heart disease (IHD) predisposition and affect coronary blood flow (CBF) regulation mechanisms. The aim of this study was to investigate the association among single nucleotide polymorphisms (SNPs) of genes encoding for proteins involved in CBF regulation and IHD. A total of 468 consecutive patients were enrolled and divided into three groups according to coronary angiography and intracoronary functional tests results: G1, patients with coronary artery disease (CAD); G2, patients with coronary microvascular dysfunction (CMD); and G3, patients with angiographic and functionally normal coronary arteries. A genetic analysis of the SNPs rs5215 of the potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) gene and rs1799983 of the nitric oxide synthase 3 (NOS3) gene, respectively encoding for the Kir6.2 subunit of ATP sensitive potassium (K
ATP ) channels and nitric oxide synthase (eNOS), was performed on peripheral whole blood samples. A significant association of rs5215_G/G of KCNJ11 and rs1799983_T/T of NOS3 genes was detected in healthy controls compared with CAD and CMD patients. Based on univariable and multivariable analyses, the co-presence of rs5215_G/G of KCNJ11 and rs1799983_T/T of NOS3 may represent an independent protective factor against IHD, regardless of cardiovascular risk factors. This study supports the hypothesis that SNP association may influence the crosstalk between eNOS and the KATP channel that provides a potential protective effect against IHD. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
13. Stereotactic Arrhythmia Radioablation Treatment of Ventricular Tachycardia: Current Technology and Evolving Indications.
- Author
-
Guarracini, Fabrizio, Tritto, Massimo, Di Monaco, Antonio, Mariani, Marco Valerio, Gasperetti, Alessio, Compagnucci, Paolo, Muser, Daniele, Preda, Alberto, Mazzone, Patrizio, Themistoclakis, Sakis, and Carbucicchio, Corrado
- Published
- 2023
- Full Text
- View/download PDF
14. The Feasibility, Effectiveness and Acceptance of Virtual Visits as Compared to In-Person Visits among Clinical Electrophysiology Patients during the COVID-19 Pandemic.
- Author
-
Mariani, Marco Valerio, Pierucci, Nicola, Forleo, Giovanni Battista, Schiavone, Marco, Bernardini, Alessia, Gasperetti, Alessio, Mitacchione, Gianfranco, Mei, Mariachiara, Giunta, Giuseppe, Piro, Agostino, Chimenti, Cristina, Miraldi, Fabio, Vizza, Carmine Dario, and Lavalle, Carlo
- Subjects
- *
COVID-19 pandemic , *PATIENT satisfaction , *ELECTROPHYSIOLOGY , *PATIENTS' attitudes , *CARDIAC patients - Abstract
The feasibility and effectiveness of virtual visits (VVs) for cardiac electrophysiology patients are still unknown. We aimed to assess the feasibility and effectiveness of VVs as compared to in-person visits, and to describe patient experience with virtual care in clinical electrophysiology. We prospectively enrolled patients scheduled to receive a clinical electrophysiology evaluation, dividing them in two groups: a VV group and an in-person visit group. Outcomes of interest were: (1) improvement in symptoms after the index visit, (2) disappearance of remote monitoring (RM) alerts at follow-up, (3) necessity of urgent hospitalization and (4) patient satisfaction measured by the Patient Satisfaction Questionnaire-18 (PSQ-18). This study included 162 patients in the VV group and 185 in the in-office visit group. As compared to in-person visits, VVs resulted in a similar reduction in RM alerts (51.5% vs. 43.2%, p-value 0.527) and in symptomatic patient rates (73.6% vs. 56.9%, p-value 0.073) at follow-up, without differences in urgent hospitalization rates (p-value 0.849). Patient satisfaction with VVs was higher than with in-person evaluation (p-value < 0.012). VVs proved to be as feasible and as effective as in-person visits, with high patient satisfaction. A hybrid model of care including VVs and in-person visits may become the new standard of care after the COVID-19 pandemic is over. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Incidence and Determinants of Spontaneous Cardioversion of Early Onset Symptomatic Atrial Fibrillation.
- Author
-
Mariani, Marco Valerio, Pierucci, Nicola, Piro, Agostino, Trivigno, Sara, Chimenti, Cristina, Galardo, Gioacchino, Miraldi, Fabio, and Vizza, Carmine Dario
- Subjects
ATRIAL fibrillation ,ELECTRIC countershock ,ATRIAL flutter ,HEART failure ,HEART beat ,BLOOD pressure ,ARRHYTHMIA - Abstract
Atrial fibrillation (AF) is the most frequent chronic arrhythmia worldwide, and it is associated with significant morbidity and mortality, making it a considerable burden both to patients and the healthcare system. Nowadays, an early attempt to restore sinus rhythm in acute symptomatic AF through electrical or pharmacological cardioversion is the most common approach in the Emergency Department (ED). However, considering the high percentage of spontaneous cardioversion of paroxysmal AF reported by many studies, this approach may not be the ideal choice for all patients. In this manuscript we performed a review of the most relevant studies found in literature with the aim of identifying the main determinants of spontaneous cardioversion, focusing on those easy to detect in the ED. We have found that the most relevant predictors of spontaneous cardioversion are the absence of Heart Failure (HF), a small atrial size, recent-onset AF, rapid Atrial Fibrillatory Rate and the relationship between a previous AF episode and Heart Rate/Blood Pressure. A number of those are utilized, along with other easily determined parameters, in the recently developed "ReSinus" score which predicts the likelihood of AF spontaneous cardioversion. Such identification may help the physician decide whether immediate cardioversion is necessary, or whether to adopt a "watch-and-wait" strategy in the presence of spontaneous cardioversion determinants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network.
- Author
-
Lavalle, Carlo, Mariani, Marco Valerio, Piro, Agostino, Magnocavallo, Michele, Vetta, Giampaolo, Trivigno, Sara, Forleo, Giovanni Battista, Della Rocca, Domenico Giovanni, Uguccioni, Massimo, Russo, Vincenzo, Summaria, Francesco, and Di Lullo, Luca
- Subjects
- *
DRUG side effects , *ORAL medication , *ANTICOAGULANTS , *ATRIAL fibrillation , *INTRACRANIAL hemorrhage - Abstract
Background: Direct oral anticoagulants (DOACs) are the preferred anticoagulant drugs for the prevention of atrial fibrillation (AF)-related thromboembolic complications and for the treatment and the prevention of recurrences of venous thromboembolism (VTE). The evaluation of self-reported adverse drug reactions (ADRs) available from databases of drug-regulatory agencies such as the Italian Medicines Agency (AIFA) pharmacovigilance database represents a novel aid to guide decision making. Objective: To assess the safety profile of DOACs by analyzing ADR rates in the real-world Italian scenario. Methods: Post-marketing surveillance data recorded by the National Pharmacovigilance Network were retrieved for the time period 2017–2021 from the AIFA online site. The following data were collected for each DOAC: total ADR number, serious ADR number, gastrointestinal (GI) ADR, intracranial hemorrhage events (ICH ADR), and more frequently reported ADR for the study year. The safety profile was expressed by the risk index (RI). Results: Rivaroxaban use was associated with consistent and stable low rates of serious ADR, GI ADR, and ICH ADR across the 5-year study period. Rivaroxaban and apixaban showed the lowest RI for serious ADR and GI ADR, while rivaroxaban use was associated with significantly lower ICH events as compared to apixaban. Dabigatran was related to the highest RIs for every ADR class, in particular GI ADRs. Conclusions: DOACs presented an acceptable safety profile in the current post-market analysis. However, rivaroxaban and apixaban were associated with more favorable safety profiles as compared to dabigatran, while rivaroxaban provoked statistically significantly fewer ICH events as compared to apixaban. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension.
- Author
-
Manzi, Giovanna, Miotti, Cristiano, Mariani, Marco Valerio, Papa, Silvia, Luongo, Federico, Scoccia, Gianmarco, De Lazzari, Beatrice, De Lazzari, Claudio, Benza, Raymond L., Fedele, Francesco, Vizza, Carmine Dario, and Badagliacca, Roberto
- Subjects
PULMONARY arterial hypertension ,HEMODYNAMIC monitoring ,INDIVIDUALIZED medicine ,PULMONOLOGY ,PATIENTS' rights - Abstract
Precision medicine, providing the right therapeutic strategy for the right patient, could revolutionize management and prognosis of patients affected by cardiovascular diseases. Big data and artificial intelligence are pivotal for the realization of this ambitious design. In the setting of pulmonary arterial hypertension (PAH), the use of computational models and data derived from ambulatory implantable hemodynamic monitors could provide useful information for tailored treatment, as requested by precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Diagnosis and Treatment of Idiopathic Premature Ventricular Contractions: A Stepwise Approach Based on the Site of Origin.
- Author
-
Muser, Daniele, Tritto, Massimo, Mariani, Marco Valerio, Di Monaco, Antonio, Compagnucci, Paolo, Accogli, Michele, De Ponti, Roberto, and Guarracini, Fabrizio
- Subjects
HEART diseases ,PROGNOSIS - Abstract
Premature ventricular contractions in the absence of structural heart disease are among the most common arrhythmias in clinical practice, with well-defined sites of origin in the right and left ventricle. In this review, starting from the electrocardiographic localization of premature ventricular contractions, we investigated the mechanisms, prevalence in the general population, diagnostic work-up, prognosis and treatment of premature ventricular contractions, according to current scientific evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives.
- Author
-
Lavalle, Carlo, Trivigno, Sara, Vetta, Giampaolo, Magnocavallo, Michele, Mariani, Marco Valerio, Santini, Luca, Forleo, Giovanni Battista, Grimaldi, Massimo, Badagliacca, Roberto, Lanata, Luigi, and Ricci, Renato Pietro
- Subjects
VENTRICULAR arrhythmia ,FLECAINIDE ,ARRHYTHMIA ,VENTRICULAR tachycardia ,HEART diseases - Abstract
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy.
- Author
-
Magnocavallo, Michele, Bellasi, Antonio, Mariani, Marco Valerio, Fusaro, Maria, Ravera, Maura, Paoletti, Ernesto, Di Iorio, Biagio, Barbera, Vincenzo, Della Rocca, Domenico Giovanni, Palumbo, Roberto, Severino, Paolo, Lavalle, Carlo, and Di Lullo, Luca
- Subjects
CHRONIC kidney failure ,ATRIAL fibrillation ,CHRONICALLY ill ,ANTICOAGULANTS ,THROMBOEMBOLISM - Abstract
Atrial fibrillation (AF) and chronic kidney disease (CKD) are strictly related; several independent risk factors of AF are often frequent in CKD patients. AF prevalence is very common among these patients, ranging between 15% and 20% in advanced stages of CKD. Moreover, the results of several studies showed that AF patients with end stage renal disease (ESRD) have a higher mortality rate than patients with preserved renal function due to an increased incidence of stroke and an unpredicted elevated hemorrhagic risk. Direct oral anticoagulants (DOACs) are currently contraindicated in patients with ESRD and vitamin K antagonists (VKAs), remaining the only drugs allowed, although they show numerous critical issues such as a narrow therapeutic window, increased tissue calcification and an unfavorable risk/benefit ratio with low stroke prevention effect and augmented risk of major bleeding. The purpose of this review is to shed light on the applications of DOAC therapy in CKD patients, especially in ESRD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels.
- Author
-
Severino, Paolo, D'Amato, Andrea, Pucci, Mariateresa, Infusino, Fabio, Birtolo, Lucia Ilaria, Mariani, Marco Valerio, Lavalle, Carlo, Maestrini, Viviana, Mancone, Massimo, and Fedele, Francesco
- Subjects
CORONARY disease ,ION channels ,HEART failure ,HEART diseases ,CORONARY circulation ,CORONARY vasospasm - Abstract
Heart failure is a complex syndrome responsible for high rates of death and hospitalization. Ischemic heart disease is one of the most frequent causes of heart failure and it is normally attributed to coronary artery disease, defined by the presence of one or more obstructive plaques, which determine a reduced coronary blood flow, causing myocardial ischemia and consequent heart failure. However, coronary obstruction is only an element of a complex pathophysiological process that leads to myocardial ischemia. In the literature, attention paid to the role of microcirculation, in the pathophysiology of ischemic heart disease and heart failure, is growing. Coronary microvascular dysfunction determines an inability of coronary circulation to satisfy myocardial metabolic demands, due to the imbalance of coronary blood flow regulatory mechanisms, including ion channels, leading to the development of hypoxia, fibrosis and tissue death, which may determine a loss of myocardial function, even beyond the presence of atherosclerotic epicardial plaques. For this reason, ion channels may represent the link among coronary microvascular dysfunction, ischemic heart disease and consequent heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist.
- Author
-
Severino, Paolo, Mather, Paul J., Pucci, Mariateresa, D'Amato, Andrea, Mariani, Marco Valerio, Infusino, Fabio, Birtolo, Lucia Ilaria, Maestrini, Viviana, Mancone, Massimo, and Fedele, Francesco
- Subjects
HEART failure ,HEART transplantation ,CARDIOGENIC shock ,HEART failure patients - Abstract
Advanced heart failure (AdHF) represents a challenging aspect of heart failure patients. Because of worsening clinical symptoms, high rates of re-hospitalization and mortality, AdHF represents an unstable condition where standard treatments are inadequate and additional interventions must be applied. A heart transplant is considered the optimal therapy for AdHF, but the great problem linked to the scarcity of organs and long waiting lists have led to the use of mechanical circulatory support with ventricular-assist device (VAD) as a destination therapy. VAD placement improves the prognosis, functional status, and quality of life of AdHF patients, with high rates of survival at 1 year, similar to transplant. However, the key element is to select the right patient at the right moment. The complete assessment must include a careful clinical evaluation, but also take into account psychosocial factors that are of crucial importance in the out-of-hospital management. It is important to distinguish between AdHF and end-stage HF, for which advanced therapy interventions would be unreasonable due to severe and irreversible organ damage and, instead, palliative care should be preferred to improve quality of life and relief of suffering. The correct selection of patients represents a great issue to solve, both ethically and economically. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.